Brineura
Classes
Lysosomal Storage Disorder Agents
Administration
Administer by intraventricular route using the provided Administration Kit.
Visually inspect parenteral products for particulate matter and discoloration prior to administration. Cerliponase alfa is a clear to slightly opalescent and colorless to pale yellow solution. Intraventricular Electrolytes is a clear to colorless solution.
Cerliponase alfa may occasionally contain thin translucent fibers or opaque particles. These naturally occurring particles are cerliponase alfa and are removed via the 0.2 micron inline filter.
Intraventricular Electrolytes may contain particles, which appear during the thaw period; however, these will dissolve when the solution reaches room temperature.
Visually inspect the Administration Kit infusion components to ensure the components are in the individual packages and have not been compromised.
Thaw cerliponase alfa and Intraventricular Electrolytes injection vials at room temperature for approximately 60 minutes; condensation will occur during thawing period. Do NOT thaw or warm vials any other way. Do NOT shake vials. Do NOT re-freeze vials or freeze syringes containing cerliponase alfa or Intraventricular Electrolytes.
Administer the complete infusion (cerliponase alfa and Intraventricular Electrolytes) using an infusion set with a 0.2 micron inline filter.
Intraventricular Infusion of Cerliponase alfa
Administer pre-medication 30 to 60 minutes prior to the start of infusion.
Using aseptic technique, label 1 sterile syringe "Brineura" and attach the syringe needle.
After removing the green flip-off caps from the 2 cerliponase alfa vials, withdraw a total of 10 mL of cerliponase alfa into the "Brineura" labeled syringe. Do not dilute or mix with any other drug.
Label the infusion line "intraventricular infusion only," attach the syringe containing cerliponase alfa to the extension line, and then connect the extension line to the infusion set with a 0.2 micron inline filter. Prime the infusion components with cerliponase alfa.
Inspect scalp for signs of intraventricular access device leakage or failure and for potential infections. Then, prepare the scalp for intraventricular infusion per institution standard of care.
Insert port needle into intraventricular access device and connect a separate empty sterile single-use luer lock syringe (no larger than 3 mL) to the port needle. Withdraw 0.5 to 1 mL of cerebrospinal fluid (CSF) to check patency of intraventricular access device and send specimen for culture. Do NOT return CSF to intraventricular access device. Routinely send CSF samples for infection monitoring.
Attach the infusion set with 0.2 micron inline filter to the port needle and secure the components per institution standard of care.
Place the "Brineura" syringe into the syringe pump, program pump to deliver at an infusion rate of 2.5 mL/hour, and set the occlusion alarm setting to alert at pressure <= 281 mmHg. Do NOT deliver as a bolus or manually.
Monitor vital signs (blood pressure, heart rate) prior to the start of infusion, periodically during infusion, and post-infusion.
During infusion, periodically inspect the infusion system for signs of leakage or delivery failure.
When the infusion is complete, detach and remove the empty syringe from the pump and disconnect from the tubing.
Storage of thawed product: Use thawed cerliponase alfa immediately. If not used immediately, store unopened vials in the refrigerator at 2 to 8 degrees C and use within 24 hours.
Storage of product in syringes: Use product held in labeled syringes immediately. If not used immediately, store product held in labeled syringes in the refrigerator at 2 to 8 degrees C up to 4 hours prior to infusion.
Intraventricular Infusion of Intraventricular Electrolytes
Intraventricular Electrolytes flush the infusion line, port needle, and intraventricular access device ensuring the full cerliponase alfa dose is administered and also maintain patency of the intraventricular access device.
Administer AFTER cerliponase alfa is complete.
Using aseptic technique, label 1 sterile syringe "Intraventricular Electrolytes" and attach the syringe needle.
After removing the yellow flip-off cap from the Intraventricular Electrolytes Injection vial, withdraw 2 mL of Intraventricular Electrolytes into the "Intraventricular Electrolytes" labeled syringe. Discard the remaining unused portion.
Attach syringe to the extension line.
Place the "Intraventricular Electrolytes" syringe into the syringe pump, program pump to deliver at an infusion rate of 2.5 mL/hour, and set the occlusion alarm setting to alert at pressure <= 281 mmHg. Do NOT deliver as a bolus or manually.
During infusion, periodically inspect the infusion system for signs of leakage or delivery failure.
When the infusion is complete, detach and remove the empty syringe from the pump and disconnect from the infusion line.
Remove the port needle and gently apply pressure. Bandage the infusion site per institution standard of care.
Dispose of the infusion components, needles, unused solutions, and other waste materials in accordance with local requirements.
Storage of thawed product: Use thawed Intraventricular Electrolytes immediately. If not used immediately, store unopened vials in the refrigerator at 2 to 8 degrees C and use within 24 hours.
Storage of product in syringes: Use product held in labeled syringes immediately. If not used immediately, store product held in labeled syringes in the refrigerator at 2 to 8 degrees C up to 4 hours prior to infusion.
Adverse Reactions
seizures / Delayed / 50.0-50.0
bradycardia / Rapid / 8.0-8.0
anaphylactoid reactions / Rapid / Incidence not known
antibody formation / Delayed / 33.0-78.0
hematoma / Early / 21.0-21.0
hypotension / Rapid / 8.0-8.0
ST-T wave changes / Rapid / Incidence not known
sinus tachycardia / Rapid / Incidence not known
hypoxia / Early / Incidence not known
fever / Early / 71.0-71.0
vomiting / Early / 63.0-63.0
irritability / Delayed / 17.0-17.0
headache / Early / 17.0-17.0
infection / Delayed / 8.0-8.0
Common Brand Names
Brineura
Dea Class
Rx
Description
Enzyme replacement therapy; recombinant tripeptidyl peptidase-1 (TPP1)
Used for symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2)
Administered directly into CSF via surgically implanted intraventricular access device
Dosage And Indications
NOTE: The FDA has designated cerliponase alfa as an orphan drug for this indication.
300 mg intraventricularly every other week. Administer cerliponase alfa first at an infusion rate of 2.5 mL/hour, then follow with the required infusion of Intraventricular Electrolytes at the same infusion rate of 2.5 mL/hour (complete infusion time is approximately 4.5 hours). Pre-treatment with antihistamines with or without antipyretics or corticosteroids is recommended 30 to 60 minutes prior to the start of the infusion.
Dosing Considerations
Specific guidelines for dosage adjustments in hepatic impairment are not available; cerliponase alfa has not been studied in patients with hepatic impairment.
Specific guidelines for dosage adjustments in renal impairment are not available; cerliponase alfa has not been studied in patients with renal impairment.
Drug Interactions
There are no drug interactions associated with Cerliponase alfa products.
How Supplied
Brineura Intraventricular (cardiac) Inj Sol
Maximum Dosage
Safety and efficacy have not been established.
Safety and efficacy have not been established.
300 mg/dose via intraventricular infusion once every other week.
3 to 12 years: 300 mg/dose via intraventricular infusion once every other week.
younger than 3 years: Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Mechanism Of Action
Neuronal ceroid lipofuscinosis type 2 (CLN2) disease is a neurodegenerative disease caused by a deficiency of the lysosomal enzyme tripeptidyl peptidase-1 (TPP1), which catabolizes polypeptides in the CNS. TPP1 has no known substrate specificity. Deficiency in TPP1 activity results in the accumulation of lysosomal storage materials normally metabolized by the enzyme in the central nervous system (CNS), leading to a progressive decline in motor function. Cerliponase alfa, a proenzyme, is a recombinant form of human TPP1. It is taken up by target cells in the CNS and is translocated to the lysosomes through the Cation Independent Mannose-6-Phosphate Receptor (CI-MPR, also known as M6P/IGF2 receptor). Cerliponase alfa is activated in the lysosome, and the activated proteolytic form of rhTPP1 cleaves tripeptides from the N-terminus of proteins.[61904]
Pharmacokinetics
Cerliponase alfa is administered as an intraventricular infusion. After the initial single dose administration, cerliponase alfa cerebrospinal fluid (CSF) exposure increased less than proportionally across the 3 doses studied (30 mg, 100 mg, and 300 mg). There was no apparent accumulation of cerliponase alfa in CSF or plasma when it was administered at a dose of 300 mg once every other week. The estimated CSF volume of distribution of cerliponase alfa 300 mg given intraventricularly is 245 mL, which exceeds the typical CSF volume of 100 mL. Cerliponase alfa is a protein and is expected to be degraded through peptide hydrolysis.
Pregnancy And Lactation
There are no available data on cerliponase alfa use during pregnancy to inform a drug-associated risk of pregnancy-related outcomes. Animal studies have not been conducted using cerliponase alfa.
There are no data on the presence of cerliponase alfa in human milk, the effects on a breast-fed infant, or the effects on milk production. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally administered drug, healthcare providers are encouraged to report the adverse effect to the FDA.